In vivo activity of aryl ozonides against Schistosoma species

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 2, 2012, Pages 1090-1092

  Keiser, Jennifer ^a,b   Ingram, Katrin ^a,b   Vargas, Mireille ^a,b   Chollet, Jacques ^a,b   Wang, Xiaofang ^c   Dong, Yuxiang ^c   Vennerstrom, Jonathan L ^c  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,4 TRIOXANE; 1,2,4 TRIOXOLANE DERIVATIVE; 1,2,4,5 TETRAOXANE; 8' ARYL OZONIDE DERIVATIVE; ANTISCHISTOSOMAL AGENT; ARTEROLANE; MT 23; OZ 154; OZ 165; OZ 27; OZ 288; OZ 401; OZ 418; OZ 439; OZ 47; OZ 508; OZ 513; PRAZIQUANTEL; ST 28; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; FEMALE; IN VIVO STUDY; MALARIA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCHISTOSOMIASIS HAEMATOBIA; SCHISTOSOMIASIS MANSONI; SINGLE DRUG DOSE; WORM INFECTION;

ANIMALS; ANTHELMINTICS; FEMALE; HETEROCYCLIC COMPOUNDS; MICE; SCHISTOSOMA HAEMATOBIUM; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS HAEMATOBIA; SCHISTOSOMIASIS MANSONI; TREATMENT OUTCOME;

EID: 84862940983     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05371-11     Document Type: Article

References (19)

1. Boissier J, Cosledan F, Robert A, Meunier B. 2009. In vitro activities of trioxaquines against Schistosoma mansoni. Antimicrob. Agents Chemother. 53:4903-4906.
2. Charman SA, et al. 2011. Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria. Proc. Natl. Acad. Sci. U. S. A. 108:4400-4405.
3. Dong Y, et al. 2005. Spiro and dispiro-1,2,4-trioxolanes as antimalarial peroxides: charting a workable structure-activity relationship using simple prototypes. J. Med. Chem. 48:4953-4961. (Pubitemid 41033136)
4. Dong Y, et al. 2006. Effect of functional group polarity on the antimalarial activity of spiro and dispiro-1,2,4-trioxolanes. Bioorg. Med. Chem. 14:6368-6382. (Pubitemid 44224072)
5. Gryseels B, Polman K, Clerinx J, Kestens L. 2006. Human schistosomiasis. Lancet 368:1106-1118. (Pubitemid 44402679)
6. Keiser J, et al. 2009. Mefloquine-an aminoalcohol with promising antischistosomal properties in mice. PLoS Negl. Trop. Dis. 3:e350.
7. Keiser J, Manneck T, Vargas M. 2011. Interactions of mefloquine with praziquantel in the Schistosoma mansoni mouse model and in vitro. J. Antimicrob. Chemother. 66:1791-1797.
8. Keiser J, et al. 2011. Efficacy and safety of artemether in the treatment of chronic fascioliasis in Egypt: exploratory phase-2 trials. PLoS Negl. Trop. Dis. 5:e1285.
9. Keiser J, Utzinger J. 2007. Advances in the discovery and development of novel trematocidal drugs. Expert Opin. Drug Discov. 2:9-23.
10. Keiser J, Utzinger J. 2007. Artemisinins and synthetic trioxolanes in the treatment of helminth infections. Curr. Opin. Infect. Dis. 20:605-612. (Pubitemid 350059520)
11. Obonyo CO, Muok EM, Mwinzi PN. 2010. Efficacy of artesunate with sulfalene plus pyrimethamine versus praziquantel for treatment of Schistosoma mansoni in Kenyan children: an open-label randomised controlled trial. Lancet Infect. Dis. 10:603-611.
12. Pradines V, et al. 2011. Trioxaquine PA1259 alkylates heme in the blood-feeding parasite Schistosoma mansoni. Antimicrob. Agents Chemother. 55:2403-2405.
13. Ramirez B, et al. 2007. Schistosomes: challenges in drug screening. Expert Opin. Drug Discov. 2:53-61.
14. Rollinson D. 2009. A wake up call for urinary schistosomiasis: reconciling research effort with public health importance. Parasitology 136:1593-1610.
15. Taniguchi T, et al. 2011. Schistosomicidal and antifecundity effects of oral treatment of synthetic endoperoxide N-89. Parasitol. Int. 60:231-236.
16. Utzinger J, N'Goran KE, Caffrey CR, Keiser J. 2011. From innovation to application: social-ecological context, diagnostics, drugs and integrated control of schistosomiasis. Acta Trop. 120(Suppl. 1):121-137.
17. Vennerstrom JL, et al. May 2008. Spiro and dispiro 1,2,4-trioxolane antimalarials. US patent 7,371,778.
18. Wang X, et al. 2011. The activity of dispiro peroxides against Fasciola hepatica. Bioorg. Med. Chem. Lett. 21:5320-5323.
19. Xiao SH, et al. 2007. The in vitro and in vivo activities of synthetic trioxolanes on major human schistosome species. Antimicrob. Agents Chemother. 51:1440-1445.